clinical trial · NCT02296684
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Cancer of Head and NeckHead and Neck CancerNeoplasms, Head and NeckCarcinoma, Squamous Cell of Head and NeckSquamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma, Head and NeckMK-3475 (neoadjuvant)SurgeryIntensity modulated radiation therapyImage-guided radiation therapyCisplatinMK-3475 (adjuvant)Peripheral blood
brief summary
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.
started
Mar 25, 2015
primary completion
Apr 5, 2022
completion
Jul 21, 2025
last updated
Aug 5, 2026
official title
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol